Challenges in the Management of Prostate Cancer-Reference-Cited by-同舟云学术

Challenges in the Management of Prostate Cancer

Published:1992-11 Issue: Volume:70 Page:33-38
ISSN:0007-1331
Container-title:British Journal of Urology
language:en
Short-container-title:

Author:

CRAWFORD E. D.

Publisher

Wiley

Subject

Urology,Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.1992.tb15865.x/fullpdf

Reference50 articles.

1. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer;Ahmann;J. Clin. Oncol.,1987

2. Long-term results of treating advanced prostatic cancer with the LH-RH analogue Zoladex;Beacock;Am. J. Clin. Oncol.,1988

3. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer;Belanger;J. Endocrinol. Metab.,1984

4. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clincal results;Borgmann;Am. J. Clin. Oncol.,1988

5. Cancer statistics, 1991;Boring;Ca-A Cancer J. Clinicians,1992

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Could the kinetin riboside be used to inhibit human prostate cell epithelial–mesenchymal transition?;Medical Oncology;2020-02-06

2. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond;The Journal of Steroid Biochemistry and Molecular Biology;2017-02

3. Hemostatic gelatin sponge is a superior matrix to matrigel for establishment of LNCaP human prostate cancer in nude mice;The Prostate;2012-04-02

4. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice;International Journal of Oncology;2012-02-06

5. Preferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide;Cancer Letters;2010-12